Schedule III controlled substance (US)
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Controlled_substance_schedule
|
| gptkbp:abusePotential |
high psychological dependence
moderate to low physical dependence |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:example |
gptkb:anabolic_steroids
gptkb:dronabinol gptkb:ketamine gptkb:buprenorphine testosterone |
| gptkbp:hasHigherAbusePotentialThan |
gptkb:Schedule_IV_controlled_substance_(US)
|
| gptkbp:hasLowerAbusePotentialThan |
Schedule II controlled substance (US)
Schedule I controlled substance (US) |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:medicalUse |
accepted
|
| gptkbp:partOf |
gptkb:Controlled_Substances_Act_(US)
|
| gptkbp:prescriptionRequired |
yes
|
| gptkbp:refillLimit |
5 times in 6 months
|
| gptkbp:regulates |
gptkb:Drug_Enforcement_Administration
|
| gptkbp:bfsParent |
gptkb:Xyrem
gptkb:Schedule_IV_controlled_substance_(US) gptkb:oxandrolone |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Schedule III controlled substance (US)
|